The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice

Biology of Sex Differences

Volumn 2, Issue 1, 2011, Pages

  Onyimba, Jennifer A ^a   Coronado, Michael J ^a   Garton, Amanda E ^a   Kim, Joseph B ^a   Bucek, Adriana ^a   Bedja, Djahida ^b   Gabrielson, Kathleen L ^b   Guilarte, Tomas R ^a,c   Fairweather, DeLisa ^a,b  

^a The Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855182939     PISSN: None     EISSN: 20426410     Source Type: Journal    
DOI: 10.1186/2042-6410-2-2     Document Type: Article

References (47)

1. WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al: Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121: e46-e215
2. Erratum in Circulation. 2010, 121: e260.
3. Wexler RK, Elton T, Pleister A, Feldman D: Cardiomyopathy: an overview. Am Fam Physician 2009, 79:778-784.
4. Dec GW: Introduction to clinical myocarditis. In Myocarditis: From Bench to Bedside. Edited by: Cooper LT Jr, Totowa N. NY: Humana Press; 2003:257-281.
5. Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, Hetzer R: Sex and gender differences in myocardial hypertrophy and heart failure. Circ J 2010, 74:1265-1273.
6. Fairweather D, Frisancho-Kiss S, Rose NR: Sex differences in autoimmune disease from a pathologic perspective. Am J Pathol 2008, 173:600-609.
7. Cooper LT Jr: Myocarditis. N Engl J Med 2009, 360:1526-1538.
8. Cihakova D, Rose NR: Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008, 99:95-114.
9. Schoub BD, Johnson S, McAnerney JM, Dos Santos IL, Klaassen KL: Epidemic Coxsackie B virus infection in Johannesburg, South Africa. J Hyg (Lond) 1985, 95:447-455. (Pubitemid 16227124)
10. Dechkum N, Pangsawan Y, Jayavasu C, Saguanwongse S: Coxsackie B virus infection and myopericarditis in Thailand, 1987-1989. Southeast Asian J Trop Med Public Health 1998, 29:273-276. (Pubitemid 128531548)
11. Khetsuriani N, LaMonte-Fowlkes A, Oberste MS, Pallansch MA: Enterovirus surveillance-United States, 1970-2005. MMWR Surveill Summ 2006, 55:1-20.
12. Fairweather D, Rose NR: Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 2007, 41:118-122. (Pubitemid 44855640)
13. Frisancho-Kiss S, Nyland JF, Davis SE, Frisancho JA, Barrett MA, Rose NR, Fairweather D: Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rβ1 signaling and IFN-β increase inflammation in males independent from STAT4. Brain Res 2006, 1126:139-147. (Pubitemid 44880925)
14. Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Rose NR, Fairweather D: Cutting Edge: Cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 2007, 178:6710-6714. (Pubitemid 46847392)
15. + T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun 2009, 23:649-657.
16. Fairweather D, Yusung S, Frisancho-Kiss S, Barrett M, Gatewood S, Steele R, Rose NR: IL-12Rβ1 and TLR4 increase IL-1β and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 2003, 170:4731-4737. (Pubitemid 36519981)
17. Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJL, Njoku DB, Cihakova D, Silbergeld EK, Rose NR, Fairweather D: Cutting Edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol 2006, 176:6411-6415. (Pubitemid 43787822)
18. Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, Talor MV, Baldeviano GC, Frisancho-Kiss S, Gabrielson K, et al: Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008, 172:1195-1208. (Pubitemid 351671534)
19. Page KR, Jedlicka AE, Fakheri B, Noland GS, Kesavan AK, Scott AL, Kumar N, Manabe YC: Myocabacterium-induced potentiation of type I immune responses and protection against malaria are host specific. Infect Immun 2005, 73:8369-8380. (Pubitemid 41740328)
20. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JGN, Geoghegan J, Germino G, et al: Multiple-laboratory comparison of microarray platforms. Nat Methods 2005, 2:345-350.
21. Rangasamy T, Misra V, Zhen L, Tankersley GC, Tuder RM, Biswal S: Cigarette smoke-induced emphysema in A/J mice associated with pulmonary oxidative stress, apoptosis of lung cells and global alterations in gene expression. Am J Physiol Lung Cell Mol Physiol 2009, 296:L888-L900.
22. Kass DA, Kitzman DW, Alvarez GE: The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design. J Cardiac Fail 2010, 16:17-24.
23. Fairweather D, Frisancho-Kiss S, Gatewood S, Njoku D, Steele R, Barrett M, Rose NR: Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity 2004, 37:131-145. (Pubitemid 38594277)
24. Isensee J, Witt H, Pregla R, Hetzer R, Regitz-Zagrosek V, Noppinger PR: Sexually dimorphic gene expression in the heart of mice and men. J Mol Med 2008, 86:61-74.
25. Waxman DJ, Holloway MG: Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009, 76:215-228.
26. Cederbaum A: Nrf2 and antioxidant defense against CYP2E1 toxicity. Expert Opin Drug Metab Toxicol 2009, 5:1223-1244.
27. Alvarez BV, Johnson DE, Sowah D, Soliman D, Light PE, Xia Y, Karmazyn M, Casey JR: Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy. J Physiol 2007, 579:127-145.
28. Quaye IK: Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008, 102:735-742.
29. Thum T, Borlak J: Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 2002, 16:1537-1549. (Pubitemid 35154636)
30. Yeap BB, Krueger RG, Leedman PJ: Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 1999, 140:3282-3291. (Pubitemid 30650647)
31. Veenman L, Gavish M: The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol Ther 2006, 110:503-524.
32. Packard CJ: Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009, 24:358-363.
33. Do R, Kiss RS, Gaudet D, Engert JC: Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin Genet 2009, 75:19-29.
34. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao R-P, Kass DA, Wang Y: The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Nat Acad Sci USA 2001, 98:12283-12288. (Pubitemid 32959865)
35. Boheler KR, Volkova M, Morrell C, Garg R, Zhu Y, Margulies K, Seymour A-M, Lakatta EG: Sex-and age-dependent human transcriptome variability: Implications for chronic heart failure. Proc Nat Acad Sci USA 2003, 100:2754-2759. (Pubitemid 36297571)
36. Karin N: The multiple faces of CXCL12 (SDF-1β) in the regulation of immunity during health and disease. J Leukoc Biol 2010, 88:463-473.
37. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Gatewood SJL, Davis SE, Njoku DB, Rose NR: IFN-β protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-β1, IL-1β and IL-4 in the heart. Am J Pathol 2004, 165:1883-1894. (Pubitemid 39578368)
38. Diedrich M, Tadic J, Mao L, Wacker MA, Nebrich G, Hetzer R, Regitz-Zagrosek V, Klose J: Heart protein expression related to age and sex in mice and humans. Int J Mol Med 2007, 20:865-874.
39. Zordoky BN, El-Kadi AO: Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 2008, 9:122-128. (Pubitemid 351461001)
40. Tabet F, Rye K-A: High-density lipoproteins, inflammation and oxidative stress. Clin Sci 2009, 116:87-98.
41. Burke JE, Dennis EA: Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009, 50:S237-S242.
42. White H: Why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Curr Opin Cardiol 2010, 25:299-301.
43. Levy R: The role of cytosolic phospholipase A2-alpha in regulation of phagocytic functions. Biochim Biophys Acta 2006, 1761:1323-1334. (Pubitemid 44773760)
44. Biolard E, Lai Y, Larabee K, Balestrieri B, Ghomashchi F, Fujioka D, Gobezie R, Coblyn JS, Weinblatt ME, Massarotti EM, et al: A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med 2010, 2:172-187.
45. Mounier CM, Wendum D, Greenspan E, Flejou J-F, Rosenberg DW, Lambeau G: Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer 2008, 98:587-595. (Pubitemid 351214519)
46. Henderson RJ, Wasan KM, Leon CG: Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma. Lip Health Dis 2009, 8:27.
47. Von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD: Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Failure Clin 2009, 5:549-560.